FDA Panel Backs Canagliflozin-- New Class of Diabetes Drug
Johnson & Johnson recently announced that it has received a positive recommendation from the FDA Endocrinology Metabolic Drugs Advisory Committee on canagliflozin, its oral once-daily medication for type 2 diabetes. The panel voted 10 to 5 to approve the drug. The FDA usually takes the panels’ recommendation into consideration when deciding whether to approve a new drug.
If approved, canagliflozin would be the first selective sodium glucose co-transporter inhibitor approved for diabetes. The drug blocks the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels.
Read more details here.